/PRNewswire/ The Tourettes syndrome drugs market size is expected to grow by USD 598.85 million during 2022-2027, progressing at a CAGR of 6.69%. North.
/PRNewswire/ A Phase 2b clinical trial involving more than 150 children and adolescents with Tourette syndrome found ecopipam significantly reduced the.
- Net Investment Income per Share of $0.43; NAV per Share of $11.66 - - Grew Portfolio Year over Year by 40% to Record $635 Million - - Horizon Platform Ends.
- Net Investment Income per Share of $0.43; NAV per Share of $11.66 - - Grew Portfolio Year over Year by 40% to Record $635 Million - - Horizon Platform Ends.